PMID- 25776527 OWN - NLM STAT- MEDLINE DCOM- 20160504 LR - 20181113 IS - 1538-2443 (Electronic) IS - 1355-0284 (Print) IS - 1355-0284 (Linking) VI - 21 IP - 4 DP - 2015 Aug TI - Quinolinic acid/tryptophan ratios predict neurological disease in SIV-infected macaques and remain elevated in the brain under cART. PG - 449-63 LID - 10.1007/s13365-015-0334-2 [doi] AB - Activation of the kynurenine pathway (KP) of tryptophan catabolism likely contributes to HIV-associated neurological disorders. However, KP activation in brain tissue during HIV infection has been understudied, and the effect of combination antiretroviral therapy (cART) on KP induction in the brain is unknown. To examine these questions, tryptophan, kynurenine, 3-hydroxykynurenine, quinolinic acid, and serotonin levels were measured longitudinally during SIV infection in the striatum and CSF from untreated and cART-treated pigtailed macaques. Messenger RNA (mRNA) levels of KP enzymes also were measured in the striatum. In untreated macaques, elevations in KP metabolites coincided with transcriptional induction of upstream enzymes in the KP. Striatal KP induction was also temporally associated-but did not directly correlate-with serotonin losses in the brain. CSF quinolinic acid/tryptophan ratios were found to be the earliest predictor of neurological disease in untreated SIV-infected macaques, outperforming other KP metabolites as well as the putative biomarkers interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1). Finally, cART did not restore KP metabolites to control levels in the striatum despite the control of the virus, though CSF metabolite levels were normalized in most animals. Overall, these results demonstrate that cerebral KP activation is only partially resolved with cART and that CSF QUIN/TRP ratios are an early, predictive biomarker of CNS disease. FAU - Drewes, Julia L AU - Drewes JL AD - Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. FAU - Meulendyke, Kelly A AU - Meulendyke KA FAU - Liao, Zhaohao AU - Liao Z FAU - Witwer, Kenneth W AU - Witwer KW FAU - Gama, Lucio AU - Gama L FAU - Ubaida-Mohien, Ceereena AU - Ubaida-Mohien C FAU - Li, Ming AU - Li M FAU - Notarangelo, Francesca M AU - Notarangelo FM FAU - Tarwater, Patrick M AU - Tarwater PM FAU - Schwarcz, Robert AU - Schwarcz R FAU - Graham, David R AU - Graham DR FAU - Zink, M Christine AU - Zink MC LA - eng GR - P01 MH070306/MH/NIMH NIH HHS/United States GR - P40 OD013117/OD/NIH HHS/United States GR - R01 MH085554/MH/NIMH NIH HHS/United States GR - R01 MH087233/MH/NIMH NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20150317 PL - United States TA - J Neurovirol JT - Journal of neurovirology JID - 9508123 RN - 0 (Anti-Retroviral Agents) RN - 343-65-7 (Kynurenine) RN - 8DUH1N11BX (Tryptophan) RN - F6F0HK1URN (Quinolinic Acid) SB - IM MH - Animals MH - Anti-Retroviral Agents/pharmacology MH - Brain/*metabolism/virology MH - Enzyme-Linked Immunosorbent Assay MH - Gas Chromatography-Mass Spectrometry MH - Immunohistochemistry MH - Kynurenine/*metabolism MH - Macaca MH - Polymerase Chain Reaction MH - Quinolinic Acid/*metabolism MH - Simian Acquired Immunodeficiency Syndrome/*metabolism MH - Tryptophan/*metabolism PMC - PMC4512924 MID - NIHMS672850 COIS- Conflict of Interest The authors declare that they have no conflicts of interest. EDAT- 2015/03/18 06:00 MHDA- 2016/05/05 06:00 PMCR- 2016/08/01 CRDT- 2015/03/18 06:00 PHST- 2014/12/10 00:00 [received] PHST- 2015/02/24 00:00 [accepted] PHST- 2015/02/16 00:00 [revised] PHST- 2015/03/18 06:00 [entrez] PHST- 2015/03/18 06:00 [pubmed] PHST- 2016/05/05 06:00 [medline] PHST- 2016/08/01 00:00 [pmc-release] AID - 10.1007/s13365-015-0334-2 [doi] PST - ppublish SO - J Neurovirol. 2015 Aug;21(4):449-63. doi: 10.1007/s13365-015-0334-2. Epub 2015 Mar 17.